Compass Oncology Clinical Trials
At Compass Oncology - The Northwest Cancer Specialists we sponsor more clinical trials than any other cancer treatment facility in the Portland-Vancouver area.
Compass Oncology - The Northwest Cancer Specialists won the prestigious American Cancer Society of Clinical Oncology (ASCO) Clinical Trial Participation Award in 2007.
Please see below for more information on our open trials.
Breast
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic (Study #06185)
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3) (Study #08223)
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer (Study #10167)
The BEACON Study (Breast Cancer Outcomes With NKTR-102) (Study #11086)
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer (Study #11158)
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer (Study #10065)
Prostate
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (Study #10164)
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED) (Study #11167)
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (Study #10165)
Colon
A Study in Second Line Metastatic Colorectal Cancer (Study #10101)
Head and Neck
Study of PX-866 and Docetaxel in Solid Tumors (Study #10231)
Phase 1 and 2 Study of PX-866 and Cetuximab (Study #11072)
Leukemia
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Study #11078)
Lymphoma
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients (Study #09064)
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R) (Study #10215)
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) (Study #10255)
Lung
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM) (Study #07170)
Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy (Study #08035)
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC) (Study #09179)
Study of PX-866 and Docetaxel in Solid Tumors (Study #10231)
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer (Study #11064)
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population (Study #10007)
ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer (Study #10090)
Melanoma
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma (Study #10052)
Myeloma
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients (Study #08209)
Phase I/TOPS
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer (Study #10150)
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer (Study #11192)
A Phase 1 Study of LY2787106 in Cancer and Anemia (Study #09044)
A Dose-Escalation Study in Participants With Advanced Cancer (Study #09067)
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel (Study #09115)
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine (Study #11197)
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer (Study #10190)
Skin
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma (BOLT) (Study #10333)
Solid Tumors
CD 30 Screening in Nonlymphomatous Cancer (Study #11107)
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (Study #10328)
Supportive Care
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy (Study #08035)
Chemotherapy-Induced Nausea and Vomitting (CINV) (Study #10267)
|
